Product Data Sheet

BCR-ABL-IN-5

Molecular Weight: 494.37

Target: Bcr-Abl

Pathway: Protein Tyrosine Kinase/RTK

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	BCR-ABL-IN-5 (compound II) is a Bcr-Abl kinase (Breakpoint cluster region-Abelson) inhibitor. BCR-ABL-IN-5 inhibits Bcr-Abl $^{\rm WT}$ and Bcr-Abl $^{\rm T3151}$ with the IC $_{50}$ value of 0.014 μ M and 0.45 μ M, respectively. BCR-ABL-IN-5 has some anti-proliferative activity against leukemic cells $^{[1]}$.	
IC ₅₀ & Target	IC50: $6.5 \mu\text{M} (\text{K562})^{[1]}$.	
In Vitro	BCR-ABL-IN-5 (compound II) (0-100 mM, 72 hours) can inhibit the proliferation of K562 human leukemia cells ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[1]	
	Cell Line:	K562 human leukemia cell line
	Concentration:	0-100 μΜ
	Incubation Time:	72 hours
	Result:	Inhibited K562 proliferation with an IC $_{50}$ value of 6.5 $\mu\text{M}.$

REFERENCES

[1]. Ashraf K El-Damasy, et al. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity. Eur J Med Chem. 2020 Dec 1;207:112710.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA